Market Overview - The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is projected to grow from USD 258.88 billion in 2025 to USD 275.27 billion in 2026, reaching USD 374.68 billion by 2031, with a CAGR of 6.33% from 2026 to 2031 [2]. Market Drivers - There is a robust outsourcing demand for complex biologics, high-potency APIs (HPAPIs), and AI-enabled process-development platforms, which are driving market growth [3]. - Increasing outsourcing volume by large pharmaceutical companies is influenced by escalating R&D costs and pipeline complexity, leading to a preference for asset-light models that leverage CDMO expertise [5]. - The surge in biologics and complex-molecule pipelines is evident, with biological entities dominating new-drug filings, including antibody-drug conjugates and mRNA vaccines [6]. Geographic Insights - North America held a 37.95% revenue share in 2025, supported by premier biologics programs and a deep venture-capital pool [9]. - The Asia-Pacific region is expected to grow at the fastest rate of 7.18% CAGR through 2031, with significant investments in mega-plants for mAbs and oligonucleotides [10]. - Europe is experiencing steady expansion, with Germany and the UK leading in quality and innovation despite Brexit challenges [11]. Market Trends - Consolidation in the industry is evident, as seen in Novo Holdings' USD 16.5 billion acquisition of Catalent, indicating a shift towards end-to-end CDMO providers [4]. - The demand for specialist partners is amplified by the need for compliance with stringent multi-region regulatory requirements, which challenge smaller entrants [8]. Competitive Landscape - Major players in the market include Thermo Fisher Scientific, Lonza Group, Catalent, and Samsung Biologics, among others, with strategic moves and market share analysis highlighting their competitive positioning [17].

| 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 2. 股份分類 ...

证券研究报告 | 行业简评报告 2026 年 02 月 03 日 布局消费反转！ 大消费组二月消费金股 研究部/消费品 % 1m 6m 12m 绝对表现 4.3 4.6 25.0 相对表现 3.1 -8.7 1.7 资料来源：公司数据、招商证券 -10 0 10 20 30 Feb/25 May/25 Sep/25 Jan/26 (%) 消费品 沪深300 相关报告 1、《招商证券 1 月港股消费观察： 外卖反垄断如何影响港股消费股前 景？》2026-01-27 2、《大消费组一月消费金股—双节 消费亮点前瞻》2026-01-06 ❑ 轻纺 杨蕊菁：看好家居板块修复以及倍加洁益生菌业务发展 风险提示：消费下行风险，消费复苏疲软风险、宏观经济变动风险等。 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 1216 | 23.5 | | 总市值（十亿元） | 17628.3 | 15.6 | | 流通市值（十亿元） | 16321.4 | 15.9 | 行业指数 3、《招商证券 12 月港股消费观察— 1-2 月流动性改善后港股消费买什 么？》2025 ...

Core Insights - The healthcare sector in Hong Kong is experiencing significant growth opportunities driven by advancements in brain-computer interfaces, AI healthcare, and CXO services [2][18]. Group 1: Brain-Computer Interfaces - Neuralink, a company owned by Elon Musk, has commenced mass production, indicating a strong push in brain technology [2][18]. - Strong Brain Technology has completed a financing round of 2 billion yuan and is preparing for an IPO [2][18]. Group 2: AI Healthcare - Major AI companies are entering the healthcare space, with Alibaba launching "Ant Aifu" and OpenAI introducing ChatGPT Health [3][18]. Group 3: CXO Services - Companies such as WuXi AppTec, Tigermed, and Zhaoyan New Drug are forecasting net profits exceeding 100% for 2025, indicating positive performance expectations in the CXO sector [4][18]. Group 4: Market Performance - The healthcare index has shown high elasticity and volatility, with a maximum increase of 148.52% during the last pharmaceutical bull market, significantly outperforming comparable indices [8][22]. - The maximum decline since 2021 for the healthcare index was -80.73%, while the cumulative return since inception is -0.93% [10][24]. Group 5: Investment Opportunities - The Hong Kong Stock Connect Medical ETF provides a streamlined way to invest in leading healthcare companies in Hong Kong [20]. - The healthcare sector is characterized by high volatility, making it an attractive option for investors looking for significant returns [8][22].

Core Insights - The global CXO industry is entering a new phase, with leading companies adopting a strategy to build a "diversified yet centralized" global network [1] - Due to geopolitical tensions and fluctuating tariff policies, global pharmaceutical outsourcing companies need to implement cross-regional diversification strategies to balance local and overseas production capacities [1] - WuXi AppTec's (药明康德) strategic deployment over the past few years aligns with this industry consensus, demonstrating its effectiveness through consistently exceeding performance expectations [1] Financial Performance - WuXi AppTec expects total revenue to reach 45.46 billion yuan in 2025, representing a year-on-year increase of 15.84%, with a 21.40% increase in revenue from continuing operations [1] - The adjusted Non-IFRS net profit attributable to the parent company is projected to be 14.96 billion yuan, reflecting a year-on-year growth of 41.3% [1] - The company is set to achieve record-high free cash flow in 2025, supported by capital expenditures of 5.5 to 6 billion yuan [3] Global Operations - WuXi AppTec has established a global operational system with over 20 R&D and production bases across Asia, Europe, and North America, serving approximately 6,000 clients [5] - The company is accelerating global capacity expansion to create a flexible and reliable global supply chain network, which will be crucial for capturing global market opportunities [5] Strategic Partnerships - In addition to consolidating traditional markets, WuXi AppTec has made strategic moves into emerging regions, signing memorandums of understanding with NEOM and the Saudi Ministry of Health [7] - These partnerships lay the groundwork for establishing a world-class CRDMO R&D and production base in NEOM and other areas in Saudi Arabia, marking a significant step in expanding its global network into the Middle East [7]

Core Viewpoint - The domestic AI-assisted medical technology is advancing, with significant developments in the approval of innovative medical devices and the application of AI in healthcare, indicating a potential for rapid growth in the AI+ healthcare market [1][2]. Group 1: Market Performance - As of February 3, 2026, the CSI Medical and Medical Device Innovation Index (931484) increased by 0.57%, with notable gains from stocks such as Aimeike (+4.07%), Jianfan Bio (+2.36%), and Xinhengcheng (+2.29%) [1]. - The Medical Innovation ETF (516820) also rose by 0.57%, with the latest price reported at 0.36 yuan [1]. Group 2: AI in Healthcare - AI applications in smart healthcare are becoming mature, particularly in medical imaging diagnostics, where AI assists doctors in improving interpretation efficiency [2]. - Recent AI medical products have accelerated their market entry, including the "Cervical Cell Digital Pathology Image Auxiliary Diagnosis Software" approved in January 2026 and the "Yuan Zhi" model from United Imaging, which achieved over 95% accuracy in complex lesion diagnosis [2]. - The combination of technological iteration and policy support is expected to drive rapid growth in the domestic AI+ healthcare market [2]. Group 3: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability, growth potential, and R&D innovation capabilities, reflecting the overall performance of profitable and growth-oriented medical and medical device companies [2]. - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Hengrui Medicine, collectively accounting for 63.9% of the index [2].

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Aimeike with a 2.18% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past 12 days, with a peak single-day net inflow of 41.83 million yuan, totaling 234 million yuan, averaging 19.54 million yuan per day [1] - Policy support for the pharmaceutical industry is ongoing, with Shanghai accelerating the implementation of major industrial projects in fields such as integrated circuits, biomedicine, and artificial intelligence [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, accounting for 63.9% of the total index weight [2] - The success rate of Phase I clinical trials for dozens of AI-derived pipelines entering trials in 2025 is projected to be as high as 80%-90%, significantly exceeding traditional levels of 40%-65% [1]

"沃什冲击"后，市场怎么看？20260202 摘要 美联储政策与市场影响：沃什的缩表计划可能导致长端利率上升和流动 性减少，对股票和商品市场构成压力，但实际执行存在不确定性，需关 注其与特朗普政府经济目标的潜在冲突。 黄金的长期投资价值：在全球地缘政治重构和经济低增长、高债务背景 下，黄金作为稳定器和对抗不确定性的工具，长期投资吸引力依然存在， 尤其是在美元霸权衰落和债务压力难以缓解的情况下。 股市牛市基础未变：尽管近期股市波动加剧，但美联储降息通道、美国 财政扩张、中国经济转型升级以及长线资金流入等因素，共同构成 2026 年牛市的基础，短期回调不改长期看好趋势。 有色金属市场展望：短期内有色金属市场可能波动，但工业金属和化工 方向在中后端行情中通常表现出色。市场企稳后，应关注产业趋势清晰 的方向，而非简单避险，并积极配置贵金属。 化工行业周期性机会：化工行业正经历新一轮紧密周期，受供需关系向 好、利率下行和流动性充裕等因素支持，估值有望上行。建议关注细分 龙头企业，如 PTA、涤纶长丝等，以获得更好的配置效果。 Q&A 沃什被提名为美联储主席后，市场对其政策主张的反应如何？ 特朗普提名凯文·沃什担任美联储 ...

2月2日，药明康德跌2.10%，成交额34.25亿元。两融数据显示，当日药明康德获融资买入额2.07亿元， 融资偿还3.14亿元，融资净买入-1.07亿元。截至2月2日，药明康德融资融券余额合计63.64亿元。 分红方面，药明康德A股上市后累计派现140.60亿元。近三年，累计派现104.06亿元。 机构持仓方面，截止2025年9月30日，药明康德十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股2.49亿股，相比上期减少5260.71万股。华夏上证50ETF（510050）位居第七大流通股东， 持股4778.07万股，相比上期减少121.71万股。华泰柏瑞沪深300ETF（510300）位居第八大流通股东， 持股4268.15万股，相比上期减少188.65万股。中欧医疗健康混合A（003095）、易方达沪深300医药ETF （512010）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑： ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 财通证券发布研报称，化学原料药PPI长期承压，行业经历低谷。随着上游成本上涨、政策驱动出清， 以及GLP-1口服小分子、小核酸等新药产业化趋势成熟，头部原料药企业凭借卡位MNC供应链的核心优 势，有望从周期股转向创新产业链，开启第二增长曲线。 财通证券主要观点如下： 化学原料药PPI指数长期承压 过去几年，原料药行业经历了艰难时期。各类产品价格下跌，其中沙坦类、肝素类、动保类等价格已跌 至历史低位，部分龙头企业甚至处于亏损阶段。同时，集采对化药制剂的降价效应逐渐传递到上游原 料，而致原料药利润率不断下降。化学原料药PPI指数长期承压。 原料药企业有望开启第二增长曲线 投资建议：关注头部中间体、原料药及CDMO企业，建议关注诚达药业、联化科技、药明康德、凯莱 英、九州药业、奥锐特、天宇药业、康龙化成、博腾股份等。 风险提示：商业化不及预期的风险；贸易摩擦的风险；产能提升不及预期的风险。 原材料价格及汇率上涨，反内卷政策有望驱动原料药行业加速出清，同时，新兴产业趋势走向成熟，原 料药企业有望开启第二增长曲线。由于石油化工相关上游原料价格有上 ...